Parthenolide inhibits the LPS-induced secretion of IL-6 and TNF-α and NF-κB nuclear translocation in BV-2 microglia

Phytotherapy Research

Volumn 26, Issue 9, 2012, Pages 1405-1409

  Magni, Paolo ^a   Ruscica, Massimiliano ^a   Dozio, Elena ^a   Rizzi, Eleonora ^b   Beretta, Giangiacomo ^a   Facino, Roberto Maffei ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b MD'E Srl   (Italy)

Author keywords

IL 6; inflammation; microglia; migraine; NF B; parthenolide; Tanacetum parthenium; TNF

Indexed keywords

ANTIMIGRAINE AGENT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDOMETACIN; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; PARTHENOLIDE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL ACTIVATION; CELL NUCLEUS; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFICACY; DRUG STRUCTURE; IN VITRO STUDY; MICROGLIA; MIGRAINE; NERVE CELL CULTURE; NONHUMAN; PROTEIN TRANSPORT; TANACETUM PARTHENIUM; WESTERN BLOTTING;

ANIMALS; CELL LINE; INTERLEUKIN-6; LIPOPOLYSACCHARIDES; MICE; MICROGLIA; NF-KAPPA B; PROTEIN TRANSPORT; SESQUITERPENES; TANACETUM PARTHENIUM; TUMOR NECROSIS FACTOR-ALPHA;

ASTERACEAE; TANACETUM PARTHENIUM;

EID: 84866070788     PISSN: 0951418X     EISSN: 10991573     Source Type: Journal    
DOI: 10.1002/ptr.3732     Document Type: Article

References (21)

1. Awang DVC,. 1993. Feverfew fever. A headache for consumer. HerbalGram 29: 34-36.
2. Banthorpe DV, Brown GD, Janes JF, Marr IM,. 1990. Parthenolide and other volatilies in the flowerheads of Tenacetum parthenium (L.) Schultz Bip. Flavour Fragr J 5: 183-185.
3. Bartley J.,. 2009. Could glial activation be a factor in migraine? Med Hypotheses 72: 255-257.
4. Chen CF, Cheng CH,. 2009. Regulation of cellular metabolism and cytokines by the medicinal herb feverfew in the human monocytic THP-1 cells. Evid Based Complement Alternat Med 6: 91-98.
5. Cui Y, Takashima T, Takashima-Hirano M, et al,. 2009. 11C-PK11195 PET for the in vivo evaluation of neuroinflammation in the rat brain after cortical spreading depression. J Nucl Med 50: 1904-1911.
6. Curry EA, Murry DJ, Yoder C, et al,. 2004. Phase I dose escalation trial of feverfew with standardized doses of parthenolide in patients with cancer. Invest New Drugs 22: 299-305.
7. De Weerdt CJ, Bootsma HPR, Hendriks H,. 1996. Herbal medicines in migraine prevention: randomized double-blind placebo-controlled crossover trial of a feverfew preparation. Phytomedicine 3: 225-230.
8. Fiebich BL, Lieb K, Engels S, Heinrich M,. 2002. Inhibition of LPS-induced p42/44 MAP kinase activation and iNOS/NO synthesis by parthenolide in rat primary microglial cells. J Neuroimmunol 132: 18-24.
9. Hwang D, Fischer NH, Jang BC, Tak H, Kim JK, Lee W,. 1996 Inhibition of the expression of inducible cyclooxygenase and proinflammatory cytokines by sesquiterpene lactones in macrophages correlates with the inhibition of MAP kinases. Biochem Biophys Res Commun 226: 810-818.
10. Kang BY, Chung SW, Kim TS,. 2001. Inhibition of interleukin-12 production in lipopolysaccharide-activated mouse macrophages by parthenolide, a predominant sesquiterpene lactone in Tanacetum parthenium: involvement of nuclear factor-kappaB. Immunol Lett 77: 159-163.
11. Kreutzberg GW,. 1996. Microglia: a sensor for pathological events in the CNS. Trends Neurosci 19: 312-318.
12. Kwok BH, Koh B, Ndubuisi MI, Elofsson M, Crews CM,. 2001. The anti-inflammatory natural product parthenolide from the medicinal herb Feverfew directly binds to and inhibits IkappaB kinase. Chem Biol 8: 759-766.
13. Mazor RL, Menendez IY, Ryan MA, Fiedler MA, Wong HR,. 2000. Sesquiterpene lactones are potent inhibitors of interleukin 8 gene expression in cultured human respiratory epithelium. Cytokine 12: 239-245.
14. O'Neill LA, Barrett ML, Lewis GP,. 1987. Extracts of feverfew inhibit mitogen-induced human peripheral blood mononuclear cell proliferation and cytokine mediated responses: a cytotoxic effect. Br J Clin Pharmacol 23: 81-83.
15. Palavitch D, Earon G, Carasso R,. 1997. Ferfew (Tanacetum parthenium) as a prophylactic treatment for migraine: a double-blind placebo-controlled study. Phytother Res 11: 508-511.
16. Pugh WJ, Sambo K,. 1988. Prostaglandin synthetase inhibitors in feverfew. J Pharm Pharmacol 40: 743-745.
17. Reuter U, Chiarugi A, Bolay H, Moskowitz MA,. 2002. Nuclear factor-kappaB as a molecular target for migraine therapy. Ann Neurol 51: 507-516.
18. Shin SM, Cho KS, Choi MS, et al,. 2010. Urokinase-type plasminogen activator induces BV-2 microglial cell migration through activation of matrix metalloproteinase-9. Neurochem Res 35: 976-985.
19. Sumner H, Salan U, Knight DW, Hoult JR,. 1992. Inhibition of 5-lipoxygenase and cyclo-oxygenase in leukocytes by feverfew. Involvement of sesquiterpene lactones and other components. Biochem Pharmacol 43: 2313-2320.
20. Tassorelli C, Greco R, Morazzoni P, Riva A, Sandrini G, Nappi G,. 2005. Parthenolide is the component of tanacetum parthenium that inhibits nitroglycerin-induced Fos activation: studies in an animal model of migraine. Cephalalgia 25: 612-621.
21. Viswanadhan VN, Ghose AK, Revankar GR, Robins, RK,. 1989. Atomic physicochemical parameters for three dimensional structure directed quantitative structure-activity relationships. 4. Additional parameters for hydrophobic and dispersive interactions and their application for an automated superposition of certain naturally occurring nucleoside antibiotics. J Chem Inf Comput Sci 29, 163-172.